FAAH & MAGL — the ECS degradation pathways

TL;DR

• FAAH → anandamide → arachidonic acid + ethanolamine.
• MAGL → 2-AG → arachidonic acid + glycerol.
• FAAH inhibitors (URB597, PF-04457845) in clinical trials.
• CBD weakly inhibits FAAH → indirect anandamide boost.

Why are enzyme inhibitors risky?

The BIA-10-2474 disaster (Rennes 2016, one death, several hospitalisations) showed the risk of off-target effects. Selective FAAH inhibitors like PF-04457845 remain under study (Cravatt 2001; Kaur 2016).

Therapeutic potential of selective enzyme inhibition

The targeted inhibition of FAAH and MAGL represents a promising pharmacological approach that differs fundamentally from the direct activation of cannabinoid receptors. While exogenous cannabinoids such as THC non-specifically stimulate receptors throughout the body, blocking the degradation enzymes leads to an increase in the body's own endocannabinoid concentration precisely where they are physiologically needed. This site- and time-specific effect minimises the risk of undesirable systemic side effects that can occur with uncontrolled receptor activation.

In preclinical research, this selective accumulation of anandamide and 2-AG reveals interesting therapeutic approaches. Increasing endocannabinoid tone could play a crucial role in regulating pain states, inflammatory processes and stress-related disorders. Since MAGL is also responsible for the degradation of 2-AG to arachidonic acid, its inhibition simultaneously reduces the synthesis of pro-inflammatory prostaglandins. This opens up new perspectives for the treatment of chronic inflammatory diseases without causing the typical side effects of classic anti-inflammatory drugs.

• Avoidance of typical psychotropic effects through purely local elevation of endocannabinoid levels.
• Reduction of inflammatory mediators by blocking the degradation pathway to arachidonic acid.
• Potential for the development of novel pain therapies beyond classic opioids.
• Precise control of endocannabinoid tone through tailored enzyme inhibitors.

Swiss research and regulatory framework

In Switzerland, research into substances that target the endocannabinoid system is subject to strict legal requirements. The development and testing of FAAH and MAGL inhibitors fall under the supervision of Swissmedic and the Federal Office of Public Health (BAG). Since these active substances influence the body's own system without being directly classified as narcotics themselves, clinical trials must meet strict safety standards. Swiss universities and research institutes are actively involved in clarifying these biochemical processes in order to lay the foundations for future medicines.

The approval of clinical trials with such enzyme inhibitors in Switzerland requires a detailed risk analysis, particularly following historical incidents in foreign studies. Swissmedic reviews the pharmacodynamic profiles and the selectivity of the drug candidates with extreme precision to rule out off-target effects. For researchers and medical professionals in Switzerland, close cooperation with the federal authorities provides a clear framework that combines patient safety with scientific progress. This strengthens Switzerland's position as a hub for innovative cannabinoid-based research.

• Strict supervision and mandatory authorization by Swissmedic and the Federal Office of Public Health (BAG).
• Focus on patient safety through precise evaluation of pharmacological selectivity.
• Active participation of Swiss university hospitals in research into the endocannabinoid system.
• Differentiation from classic narcotics due to the indirect mechanism of action of the inhibitors.

Interaction with phytocannabinoids and dietary factors

In addition to synthetic inhibitors, natural phytocannabinoids and everyday dietary factors also influence the activity of FAAH and MAGL. For example, scientific studies suggest that cannabidiol (CBD) can weakly inhibit the FAAH enzyme, leading to a slowed breakdown of anandamide. This indirect mechanism could explain some of the calming and regulatory properties of CBD, as the body's own anandamide remains at the receptors for longer. This gentle modulation differs significantly from the abrupt blockade caused by synthetic active substances.

In addition, polyunsaturated fatty acids from the diet play an essential role as building blocks for endocannabinoids and as substrates for their degradation enzymes. A balanced intake of omega-3 and omega-6 fatty acids directly influences the biosynthesis of anandamide and 2-AG. Since FAAH and MAGL process these lipids, diet can shape enzyme activity and thus the balance of the entire endocannabinoid system in the long term. Research into these dietary influences offers preventive approaches to support the body's own regulation.

• Indirect increase in anandamide levels through gentle FAAH inhibition by CBD.
• Importance of omega fatty acids as essential precursor molecules for endocannabinoids.
• Influence of the daily diet on the activity and efficiency of degradation enzymes.
• Potential for holistic therapeutic approaches through the combination of phytocannabinoids and dietary adjustments.

Biochemical specificity and tissue distribution of the enzymes

FAAH and MAGL differ not only in their primary substrates, but also in their cellular localization and distribution in the human organism. While FAAH is mainly bound intracellularly to membranes of the endoplasmic reticulum and occurs predominantly in the brain, liver, and kidneys, MAGL is a presynaptically localized enzyme. MAGL is responsible for nearly 85 percent of the degradation of 2-arachidonoylglycerol (2-AG) in the brain. This spatial separation determines which physiological regulatory loops are primarily influenced by the respective inhibition.

The degradation kinetics also show clear differences. Anandamide is regulated relatively slowly but continuously by FAAH, whereas the degradation of 2-AG by MAGL occurs extremely rapidly to prevent synaptic overstimulation. These biochemical properties complicate the development of universal modulators. Swiss laboratories are intensively studying these dynamics to characterize selective active substances that specifically block only one of the two enzymes without jeopardizing the fragile balance of the entire endocannabinoid system.

• FAAH is primarily localized postsynaptically and preferentially degrades anandamide.
• MAGL controls the presynaptic degradation of 2-AG and is far more abundantly expressed in the brain.
• Different half-lives of the substrates require precise pharmacokinetic models.
• Selective blockade prevents the unwanted accumulation of non-target lipids.

Pharmacological hurdles and modern safety testing

The development of safe FAAH and MAGL inhibitors requires highly sophisticated screening procedures to avoid unwanted cross-reactivities. Since both enzymes belong to the large family of serine hydrolases, there is always a risk with synthetic molecules that they will also block other vital enzymes of this class. Such off-target effects can cause severe disruptions in lipid metabolism. Modern preclinical testing therefore utilizes high-resolution proteome analyses to seamlessly map the selectivity of new drug candidates before the first human trials take place.

In Switzerland, Swissmedic coordinates these approval processes under the strictest conditions. Developers must demonstrate in detail that a drug candidate binds exclusively to the target enzyme. In doing so, state-of-the-art in vitro models on human cell cultures are used to make potential toxic effects visible at an early stage. These preventive safety measures have ensured that clinical research in this area now exhibits an extremely high level of safety and that uncontrolled risks are systematically minimized.

• Belonging to the serine hydrolase family carries risks of cross-reactivity.
• Use of activity-based protein profiling (ABPP) to verify selectivity.
• Strict regulatory requirements by Swissmedic for clinical trial phases.
• Use of human cell models for the early detection of tissue toxicity.

Differentiation from direct receptor stimulation in practice

Since the legislative amendment in August 2022, medical cannabis has been prescribable by doctors in Switzerland without a BAG exceptional permit. This classic therapy is based on phytocannabinoids such as THC and CBD, which bind directly to CB1 and CB2 receptors. In contrast, the enzymatic inhibition of FAAH and MAGL does not act directly on the receptors. It merely amplifies the signal of the body's own endocannabinoids by delaying their natural degradation. This offers a completely different therapeutic approach in daily clinical practice.

While direct stimulation by THC is often associated with psychotropic side effects and the development of tolerance, the effect of enzyme inhibitors remains restricted to regions where the system is already active. Furthermore, the risk of an overdose in the classic sense is eliminated, as the body regulates the synthesis of endocannabinoids itself. For Swiss medical professionals, this method represents a potential future alternative for treating chronic pain or spasticity without the typical impairments to driving ability or cognitive performance.

• Direct receptor activation by THC leads to systemic and often psychotropic effects.
• Enzyme inhibition acts in a site- and time-specific manner only when there is a physiological need.
• Lower risk of tolerance development and dependence compared to agonists.
• Potential avoidance of conflicts with the Swiss Road Traffic Act due to the absence of intoxication.

Analytical determination of endocannabinoid levels

The measurement of anandamide and 2-AG, as well as the activity of FAAH and MAGL, poses major challenges for bioanalytical chemistry. Since these lipid-like signaling molecules are extremely unstable and degrade rapidly in blood and tissue, their determination requires specialized procedures. In Swiss university laboratories and specialized institutes, liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) is mostly used for this purpose. This highly sensitive method allows even the tiniest concentrations in the picogram range to be precisely quantified.

For clinical practice, this analysis is not yet a standard procedure, but remains primarily reserved for research. However, the exact determination of enzyme activity is essential to objectively prove the efficacy of new inhibitors in studies. Swiss research groups are working on standardized protocols to optimize sample collection and storage. This is the only way to prevent the sensitive endocannabinoids from degrading during processing and distorting the measurement results.

• High instability of anandamide and 2-AG requires immediate sample cooling and stabilization.
• LC-MS/MS as the gold standard for quantitative determination in Swiss research laboratories.
• Current limitation of analytics to academic and clinical studies.
• Development of standardized protocols to avoid pre-analytical errors.

FAQ